Solanezumab

Solanezumab is a monoclonal antibody designed for the treatment of Alzheimer's disease. Developed by Eli Lilly and Company, Solanezumab was created to recognize and bind to the amyloid-β peptides that accumulate in the brains of Alzheimer's patients.

Development and Clinical Trials

Solanezumab was developed by Eli Lilly and Company as a potential treatment for Alzheimer's disease. The drug is a monoclonal antibody that targets amyloid-β peptides, which are believed to play a key role in the development of Alzheimer's disease.

In 2016, results from a large-scale clinical trial known as EXPEDITION3 were published. The trial did not meet its primary endpoint, which was a significant slowing of cognitive decline in patients with mild Alzheimer's disease. However, some secondary analyses suggested that Solanezumab might have a modest effect on slowing cognitive decline in this patient population.

Mechanism of Action

Solanezumab is designed to bind to amyloid-β peptides in the brain. These peptides are a primary component of the amyloid plaques that are a hallmark of Alzheimer's disease. By binding to these peptides, Solanezumab is thought to facilitate their removal from the brain, thereby potentially slowing the progression of the disease.

Future Research

Despite the disappointing results of the EXPEDITION3 trial, research into Solanezumab and other amyloid-targeting therapies continues. Some researchers believe that treating patients earlier in the course of their disease, before significant brain damage has occurred, may yield more positive results.

See Also

• Alzheimer's disease
• Amyloid beta
• Monoclonal antibodies
• Eli Lilly and Company

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!